Managing prostate cancer: the role of hormone therapy.

Michelle L. Ramirez, Thomas E. Keane, Christopher P Evans

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Androgen deprivation therapy has been the mainstay of treatment for men with metastatic prostate cancer and now plays a more active role in the management of less advanced cancers as neoadjuvant and adjuvant treatment. Investigative uses include primary therapy for patients unsuitable for definitive therapy and as a complement to ablative procedures, brachytherapy, and chemotherapy. Intermittent androgen deprivation therapy is being considered as an alternative to continuous therapy and further evaluated as triple androgen blockade in conjunction with finasteride. Many accepted and potential management schemes incorporating hormonal therapy are increasingly employed despite indeterminate indications for use. Here, we review currently available data on the efficacy of hormonal therapy with regard to complete androgen ablation, primary, neoadjuvant, and adjuvant therapy. Additionally, we examine the usefulness of delayed versus immediate administration, intermittent androgen deprivation, and other prospective applications for hormonal therapy.

Original languageEnglish (US)
Pages (from-to)10-18
Number of pages9
JournalThe Canadian journal of urology
Volume14 Suppl 1
StatePublished - Dec 2007

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Managing prostate cancer: the role of hormone therapy.'. Together they form a unique fingerprint.

Cite this